Conservative management of placenta percreta

Yogita Gavit*, Deepika Sharma

INTRODUCTION

The incidence of placenta accreta, increta, percreta, collectively called placenta accrete spectrum disorders, has been rising dramatically over the last decade worldwide, mainly due to rising cesarean delivery rate. Antenatal diagnosis and making no attempt to remove any parts of placenta is associated with reduced levels of hemorrhage and therefore less blood transfusion. Although elective cesarean hysterectomy is the standard practice, the choice of conservative management has emerged into practice. Conservation of the uterus reduces numerous short- and long-term complications including massive blood transfusion, disseminated intravascular coagulopathy, high morbidity and mortality rates, adjacent pelvic organ damage, infection as well as long term psychological sequela, due to loss of femininity and fertility. Hereby representing a model for the follow up of conservative management of placenta percreta. Sequential changes in symphysial fundal height, serum beta-HCG and ultrasonographic volume of the placenta mass were used as combined methods for the follow up of the case. The placental volume was calculated by using a 2-dimensional ultrasound scan by measuring the maximum length and anteroposterior and transverse diameters of the uterus and using the formula for the volume of prolate ellipsoid.

Keywords: Placenta percreta, Conservative management

CASE REPORT

Mrs. XYZ gravida 2 para 1 living (G2P1L1) with 35 weeks of gestation with previous one lower segment cesarean section (LSCS) was diagnosed with placenta percreta at 32 weeks of gestation. Two-dimensional grayscale ultrasound showed features of morbid adherence (loss of cleat zone, presence of abnormal placental lacunae, bladder wall interruption and myometrium thinning). 2D color doppler revealed uterovesical hypervascularity and bridging and possible bladder wall involvement findings was confirmed by doing MRI 1.5 Tesla which reported placenta percreta (protrusion of placental tissue beyond the outer confines of uterine myometrium, increased vascularity between serosa and bladder). After complete blood investigation which was with normal limits and explaining approach of
management and its risk informed consent taken, patient underwent elective classical cesarean section under epidural anesthesia. Intra-operative findings: - uterovesical hypervascularity, bridging vessel and posterior bladder wall involvement.

Figure 1: (A) ultrasound grayscale image thin tissue rim (arrow) between placenta (P) and the urinary bladder (UB), representing previous C-section scar (B) colour doppler image presents placental flow immediately next to UB lumen (C) MRI depicts placental tissue invades UB (D) MRI depicts P bulging anterior inferiorly against UB structure with only thin rim interposed tissue.

Figure 2: Intra-operative placenta percreta.

Baby delivered by vertex presentation cried immediately after birth weighing 2900 grams, maternal end umbilical cord tie, placenta was kept in situ uterine incision sutured with vicryl no 1, intra-operatively 2-pint pack cell volume; 4-pint Fresh Frozen Plasma; 2-pint platelet transfused, evidence of 600 ml blood loss. Prohalactically right side internal iliac artery ligation done, left side was not accessible and homeostasis was achieved at systolic blood pressure 110 mmhg (millimeter of mercury) abdomen was closed.

Intra-operative uneventful. Patient shifted to intensive care unit started injection piperacillin 4.45 gm 12 hourly, injection metronidazole 400 mg 12 hourly, antiemetics for 3 days followed with oral antibiotics for 5 days and conservative treatment with injection methotrexate 1 mg/kg administered post-delivery given weekly for 4 weeks along with alternate day injection lecouvorin 0.1 mg/kg day weekly for 4 weeks and patient was monitored with blood investigation, symphsial fundal height, placental volume every 14 days till it subsided.

Table 1: Investigation chart.

| Day               | Pre-operative | Post-operative day 2 | Post-operative day 6 | Post-operative day 12 | Post-operative day 26 | Post-operative day 54 |
|-------------------|---------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Hb gm%            | 9.9           | 8.7                  | 9.0                  | 9.2                  | 9.7                  | 10                   |
| WBC cmm           | 8000          | 10000               | 75000               | 7000                 | 5800                 | 5200                 |
| Platelet cmm      | 2450000       | 2380000             | 2320000             | 2300000              | 2400000              | 2460000              |
| Total Bilirubin   | 0.5           | 0.5                  | 0.6                  | 0.5                  | 0.6                  | 0.6                  |
| SGPT/SGOT         | 28/27         | 28/25                | 22/26                | 25/27                | 22/26                | 20/22                |
| BUN               | 10            | 9                    | 10                   | 12                   | 10                   | 10                   |
| Creatinine        | 0.8           | 0.8                  | 0.8                  | 0.7                  | 0.7                  | 0.77                 |
| PT/INR            | 16/10         | 16/1.2               | 16/1.1               | 15/1.0               | 15/1.0               | 15/0.9               |

Hb- hemoglobin, WBC-white blood cell count, cmm- cubic millimeter, SGPT-serum glutamic-pyruvic transaminase, SGOT-serum glutamic-oxaloacetic transaminase, BUN- blood urea nitrogen, PT/INR-prothrombin time /India normalized ration.

Table 2: Sequential changes in the clinical, bio-chemical, radiographical parameters.

| Day               | Symphysial fundal height(cm) | Serum beta HCG(IU/ml) | Placental volume (ml) |
|-------------------|-----------------------------|-----------------------|-----------------------|
| Pre-operatively   | 34                          |                       |                       |
| Post-op day 6     | 25                          | 26679                 | 1450                  |
| Post-op day 12    | 24                          | 8900                  | 1073                  |
| Post-op day 26    | 24                          | 1256                  | 1030                  |

Continued.
DISCUSSION

There are three varieties of placenta accreta: placenta accrete in which there is no dividing line between the decidua compacta and decidua spongiosa, nor can operator establish any line of cleavage between the placenta and uterine wall; placenta increta in which the chorionic villi make contact with, but not invade the myometrium; placenta percreta in which the whole thickness of the myometrium is invaded to serosal surface with the possibility of rupture into peritoneal cavity. Known risk factors are manual removal of placenta at a previous birth, vigorous and repeated curettage, presence of submucous fibroid, placenta praevia, pregnancy in uterine diverticulum, previous cesarean section scar.

Maternal and perinatal morbidity is common in pregnancies with placenta percreta due to uterine rupture, blood loss, and ureteral ligation in pregnancies, fistula formation or infection. The option for treatment includes surgical removal of the uterus or conservative treatment with the placenta left in situ. In literature seven cases have been reported of conservative management of placenta percreta or placenta accrete with methotrexate. We decided to start treatment with methotrexate due placenta deeply penetrating into bladder (muscularis wall) which was inaccessible to operate. It is suggested that Methotrexate acts not only on the dividing trophoblast cells but has effects on neovascularization and growth factors as well. Methotrexate has been shown to decrease trophoblast activity and to reduce placenta vascularity. After treatment with methotrexate, the placental size, serum beta HCG, symphsial fundal size was assessed every 14 days, reduced significantly after four courses. Our case demonstrates that conservative treatment for placenta percreta can be successful. By leaving a placenta accreta in situ after the delivery of the fetus, one can expect a progressive decrease in blood supply within the uterus, parametrium, and the placenta. This will result in secondary necrosis of the villous tissue, and thus the placenta should progressively detach itself from the uterus (and from the adjacent pelvic organs), finally to resorb or be expelled without significant complications. A large multicenter study in France with 167 cases of PAS disorders found an overall success rate of uterine preservation to be 78% in expectant approach, while the placenta resorbed spontaneously in 75% of cases (median: 13.5 weeks).

The aim of the follow-up of these patients is to identify the women at risk for complications like delayed hemorrhages, endomyometritis, sepsis, uterocutaneous fistula for early intervention and to decrease the morbidity rate. We used fundal height, placental volume, and serum beta-HCG in the follow-up. Placental volume measured in ultrasound scan became 50-52 ml after 120 days in our case. Most reviews and guidelines recommended ultrasonographic follow-up for patients undergoing conservative management. Roulout et al reported in their case series that the appearance of an anechoic range on the remaining placental tissue could announce close elimination of the placenta. Furthermore, they found that the cessation of vascularization of the placental site took on average 47 days, corresponding clinically to the arrest of irregular vaginal bleeding described by the patients. Measurement of the pulsatility index (PI) of the uterine arteries is a noninvasive method that has been proposed for 4 case reports in obstetrics and gynecology use in the follow-up of conservative management of placenta accreta. With placental resorption, the low resistance flow of the placental bed disappears, resulting in an increase in PI of uterine arteries. The rising PI is associated with effective conservative management.

CONCLUSION

The lifesaving modality of management is the early diagnosis of this condition. A multi-level disciplinary approach is the line of management. An increase number of cesarean sections and uterine curettages have increased the rate of abnormal placentation hence it is necessary to optimize the protocols required for management of these procedures. Conservative treatment may be alternative procedure in some selected cases of placenta percreta. Patients and expertise must be warned about the risk of secondary complications these risks must reserve this management to centers with experience. Peripartum hysterectomy is the definitive management for placenta accrete disorders terminates woman’s reproductive capacity though it is a lifesaving procedure.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Committee on Obstetrics Practice, “ACOG committee opinion Placenta accrete Number 266, January 2002. America College of Obstetrics & Gynecologists. Int J Gynecol Obstet. 2002;1:77-8.
2. Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta obstetricia et gynecologica Scandinavica. 2011;90(10):1140-6.
3. Hunt JC. Conservative management of placenta accreta in a multiparous woman. J Preg. 2010;0:2010.
4. Ghosh M, Chandraharan E. Management of post-partum haemorrhage. Obstet Gynaecol Reproduct Med. 2017;27(8):239-44.
5. Gupta D, Sinha R. management of placenta accrete with oral Methotrexate. Int J Gynaecol Obstet. 1998; 60:171-3.
6. Kirkinen P, Dudenhausen J, Baumann H, Huch R. Postpartum blood flow velocity waveforms of the uterine arteries . J Reprod Med. 1998;33:745-8.
7. Flam F, Kalstrom FP-OP, Carlsson B, Saroff L. Methotrexate for retained placental tissue. Eur Obstet Gynecol Reprod Biol. 1999;83:127-9.
8. Fox KA, Shamshirsaz AA, Carusi D, Secord AA, Lee P, Turan OM, et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol. 2015;213(6):755-60.
9. Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta obstetricia et gynecologica Scandinavica. 2014;93(2):138-43.
10. Hayes E, Ayida G, Crocker A. The morbidity adherent placenta: diagnosis and management options. Cur Opin Obstet Gynecol. 2011;23(6):448-53.
11. Royal College of Obstetricians and Gynaecologists, “Green-top Guideline No. 27. Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management,” RCOG, London, 2011.
12. Roulot A, Barranger E, Morel O, Soyer P. Héquet D. Apport de l’échographique 2D/3D dans le suivi de l’élimination du résidu placentaire après traitement conservateur de placenta accreta. J Obstet Gynecol Biol Reprod. 2015;44(2):176-83.
13. Matsumura N, Inoue T, Fukuoka M, Sagawa N, Fujii S. Changes in the serum levels of human chorionic gonadotropin and the pulsatility index of uterine arteries during conservative management of retained adherent placenta. J Obstet Gynaecol Res. 2000;26(2):81-7.
14. Jain A, Sepulveda W, Paterson-Brown S. Conservative management of major placenta previa accreta: three case reports. J Obstet Gynaecol. 2004;24(1):863.

Cite this article as: Gavit Y, Sharma D. Conservative management of placenta percreta. Int J Reprod Contracept Obstet Gynecol 2020;9:5140-3.